T2DM treatment: Early intensification and CV risk-factor co-management new norm

Dr Danish Ng Ooi Yee, a consultant endocrinologist and internist, discusses the paradigm shift in the type 2 diabetes mellitus (T2DM) treatment landscape, where physicians are now shifting from glucocentric approach to one that also covers cardiovascular risk factors and kidney protection. Ng also highlights a case presentation involving the use of a fixed dose combination of a sodium/glucosecotransporter-2 inhibitor (SGLT-2i) and dipeptidyl peptidase-4 enzyme inhibitor (DPP-4i) in the management of a T2DM patient.